Skip to content

Effects of dexmedetomidine or remifentanil on postoperative comfort, liver function and prognosis during radiofrequency ablation of liver cancer

Effects of dexmedetomidine or remifentanil on postoperative comfort, liver function and prognosis during radiofrequency ablation of liver cancer

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-15006613
Enrollment
Unknown
Registered
2015-06-17
Start date
2015-06-23
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic carcinoma

Interventions

Dexmedetomidine :Dexmedetomidine

Sponsors

The Third Affiliated Hospital of Sun Yat Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Child-Pugh A or B, age l8 ~ 65, ASA I or II ; primary liver cancer diagnosis and staging: single tumor, maximum diameter <=5 cm, or the number of tumor <=3, the largest diameter <=3 cm. To accept the radiofrequency ablation for the first time.

Exclusion criteria

Exclusion criteria: Patients have received other non-medical treatment (such as TACE, tumor resection, radiofrequency ablation, etc.); untreated or uncontrolled high blood pressure; arrhythmias or other cardiovascular disease; patients with chronic obstructive pulmonary disease; patients with mental illness who can not cooperate; severe liver dysfunction; renal impairment; taking alpha 2 receptor agonist recently; allergy to the drugs.

Design outcomes

Primary

MeasureTime frame
heat rate;blood pressure;sevoflurane concentration;BIS;albumin;Aspartate aminotransferase;Prothrombin Time;Total bilirubin;VAS;

Countries

China

Contacts

Public ContactZiqing Hei
heiziqing@sina.com+86 20 13925020330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026